Modulating the histamine H4 receptor enhances anti-tumor efficacy in a mouse model of breast cancer - Takeaways - MDSpire

Modulating the histamine H4 receptor enhances anti-tumor efficacy in a mouse model of breast cancer

  • By

  • Ramiro Vázquez

  • Paula Saibene

  • Maria Emilia Boix

  • Mariano Maio

  • Gabriela Salamone

  • Luciana Balboa

  • Mónica Vermeulen

  • April 21, 2026

  • 0 min

Share

  • 1

    Histamine H4 receptor (H4R) blockade inhibits tumor cell proliferation and migration in a mouse model of breast cancer.

  • 2

    The specific antagonist JNJ777120 enhances anti-tumor efficacy by altering energy metabolism and immune response.

  • 3

    In vivo studies show that H4R blockade increases CD8+ lymphocyte recruitment and lymphocyte proliferation in tumors.

  • 4

    Histamine's role in breast cancer is context-dependent, influencing tumor growth and the immune microenvironment.

  • 5

    The findings suggest H4R as a potential therapeutic target for improving breast cancer treatment outcomes.

Original Source(s)

Modulating the histamine H4 receptor enhances anti-tumor efficacy in a mouse model of breast cancer

  • by Ramiro Vázquez, Paula Saibene, Maria Emilia Boix, Mariano Maio, Gabriela Salamone, Luciana Balboa, Mónica Vermeulen

  • April 21, 2026

Related Content

Depression and breast cancer: research progress and prospects from an interdisciplinary perspective

Diagnostic value of multimodal ultrasound imaging in triple-negative breast cancer

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

  • May 26, 2026

  • 5 min